•
AL
ALGS
Aligos Therapeutics, Inc. Common Stock
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
49.29M
Volume
80.97K
52W High
$34.37
52W Low
$3.76
Open
$8.13
Prev Close
$8.01
Day Range
7.77 - 8.99
About Aligos Therapeutics, Inc. Common Stock
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Latest News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Dec 12
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Nov 14
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•May 16
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Mar 14
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
GlobeNewswire Inc.•Mar 3
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Dec 13
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Oct 11
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
GlobeNewswire Inc.•Oct 1